Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases

Seres Therapeutics Inc MCRB has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval.
SER-109 is an oral, live microbiome therapy under development for patients with recurrent C. difficile infection, a leading cause of hospital-acquired infections in the U.S.
The candidate is made up of purified Firmicutes spores, a type of bacteria.
Under the new deal, Nestlé’s global pharmaceutical business, Aimmune Therapeutics, will take the lead on commercialization.
Seres will secure $175 million upfront, plus another $125 million if the candidate gets FDA approval.
The agreement also includes sales target milestones of up to $225 million, and Seres is entitled to 50% of the commercial profits.
In August 2020, Seres announced that SER-109 had met the primary endpoint in the Phase 3 ECOSPOR III study, showing a highly statistically significant reduction in the rate of CDI recurrence compared to placebo at eight weeks, with an absolute decrease of 27% and a relative risk reduction of 68%.
In a separate measure, approximately 88% of patients achieved sustained clinical response at week eight.
The drug’s in an ongoing open-label safety study, with enrollment to complete in the third quarter. Seres and Nestlé are hoping the efficacy results will support a marketing application filing “once the SER-109 safety database includes at least 300 treated subjects monitored for 24 weeks,” based on feedback from the FDA.
MCRB Price Action: MCRB shares were down 1.93% at $23.39 at last check Thursday.
Editor’s note: Second last bullet has been updated to note that the enrollment will be completed by the third quarter, but the company did not specify when the study results are anticipated.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga